Bevacizumab treatment for advanced non‑small cell lung cancer: A case report

Fan,Yun; Huang,Zhiyu; Mao,Weimin

doi:10.3892/ol.2013.1603

Bevacizumab treatment for advanced non‑small cell lung cancer: A case report

Authors:
- Yun Fan
- Zhiyu Huang
- Weimin Mao
View Affiliations

Affiliations: Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: October 4, 2013 https://doi.org/10.3892/ol.2013.1603
Pages: 1779-1783

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The safety of Avastin in lung cancer (SAiL) study is a multi‑center, open‑source, stand‑alone study. Patients with untreated, locally advanced, metastatic or recurrent non-squamous non‑small cell lung cancer (NSCLC) were administered up to six cycles of chemotherapy combined with bevacizumab‑humanized monoclonal antibodies, followed by maintenance therapy with bevacizumab until further progression of the disease. From August, 2006 to July, 2008 there were a total of 2,172 patients enrolled in the study, with a median progression‑free survival time of 7.8 months and an overall survival time of 14.6 months. The present study describes the case of a 54‑year‑old male with lung cancer and T3N0M1 subcutaneous metastasis, which was initially treated with bevacizumab‑combined carboplatin/paclitaxel (C/P) therapy and then maintained solely with bevacizumab for five years. Following six cycles of C/P bevacizumab treatment, the therapeutic evaluation revealed a stable disease (SD). The patient was kept on bevacizumab maintenance therapy for 50 months without disease progression until a persistent 3+ proteinuria was diagnosed in a follow‑up review, which led to bevacizumab withdrawal and concomitant tumor growth. The present study concluded that the long‑term application of bevacizumab monoclonal antibodies (mABs) was safe in a late‑stage non‑small cell lung cancer patient. The major adverse reaction that was exhibited was proteinuria, which was associated with the cumulative dose of bevacizumab and was able to be reversed by withdrawal. Patients with a prolonged SD may benefit from bevacizumab maintenance therapy.

View Figures

View References

1	Bareschino MA, Schettino C, Rossi A, et al: Treatment of advanced non small cell lung cancer. J Thorac Dis. 3:122–133. 2011.PubMed/NCBI
2	Crinò L, Dansin E, Garrido P, et al: Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 11:733–740. 2010.PubMed/NCBI
3	Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
4	Sandler A, Yi J, Dahlberg S, et al: Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 5:1416–1423. 2010. View Article : Google Scholar : PubMed/NCBI
5	Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 27:1227–1234. 2009. View Article : Google Scholar : PubMed/NCBI
6	Reck M, von Pawel J, Zatloukal P, et al; BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 21:1804–1809. 2010. View Article : Google Scholar : PubMed/NCBI
7	Yuan F, Chen Y, Dellian M, et al: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA. 93:14765–14770. 1996. View Article : Google Scholar
8	Mancuso MR, Davis R, Norberg SM, et al: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 116:2610–2621. 2006. View Article : Google Scholar : PubMed/NCBI
9	Bagri A, Berry L, Gunter B, et al: Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res. 16:3887–3900. 2010. View Article : Google Scholar : PubMed/NCBI
10	Ebos JM, Lee CR, Cruz-Munoz W, et al: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15:232–239. 2009. View Article : Google Scholar : PubMed/NCBI
11	Nadler E, Yu E, Ravelo A, Sing A, Forsyth M and Gruschkus S: Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist. 16:486–496. 2011. View Article : Google Scholar : PubMed/NCBI
12	Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non - small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 19:3210–3218. 2001.PubMed/NCBI
13	Scagliotti GV, De Marinis F, Rinaldi M, et al; Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 20:4285–4291. 2002. View Article : Google Scholar : PubMed/NCBI
14	Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar
15	Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
16	Gridelli C, Ardizzoni A, Douillard JY, et al: Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer. 68:319–331. 2010. View Article : Google Scholar : PubMed/NCBI
17	Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI